RhumbLine Advisers
AKCA

RhumbLine Advisers’s Akcea Therapeutics Inc AKCA Stock Holding History

RhumbLine Advisers’s Portfolio AKCA Stock Details AKCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-22,512
Closed -$408K – 3072
2020
Q3 		$408K Sell
22,512
-3,160
-12% -$44.8K ﹤0.01% 2382
2020
Q2 		$352K Buy
25,672
+8,521
+50% +$131K ﹤0.01% 2496
2020
Q1 		$245K Buy
17,151
+127
+0.7% +$2.08K ﹤0.01% 2492
2019
Q4 		$288K Buy
17,024
+184
+1% +$3.42K ﹤0.01% 2617
2019
Q3 		$259K Sell
16,840
-125
-0.7% -$2.66K ﹤0.01% 2642
2019
Q2 		$398K Sell
16,965
-194
-1% -$4.79K ﹤0.01% 2459
2019
Q1 		$486K Buy
17,159
+409
+2% +$11.9K ﹤0.01% 2340
2018
Q4 		$505K Buy
16,750
+5,208
+45% +$146K ﹤0.01% 2294
2018
Q3 		$404K Sell
11,542
-704
-6% -$21.3K ﹤0.01% 2366
2018
Q2 		$290K Sell
12,246
-818
-6% -$19.5K ﹤0.01% 2552
2018
Q1 		$335K Buy
13,064
+1,695
+15% +$36.5K ﹤0.01% 2385
2017
Q4 		$197K Sell
11,369
-1,393
-11% -$27.3K ﹤0.01% 2637
2017
Q3 		$353K Buy
+12,762
New +$236K ﹤0.01% 2493

RhumbLine Advisers's AKCA Position: Q4 2020 in Review

RhumbLine Advisers sold out of Akcea Therapeutics Inc (AKCA) in Q4 2020, closing a stake of 22,512 shares — an estimated $408K sold.

RhumbLine Advisers first reported a position in AKCA in Q3 2017 and held it in 13 quarters. The position peaked at $505K in Q4 2018. 0 funds tracked by Wall St. Rank hold AKCA as of Q4 2020.

  • RhumbLine Advisers reported no remaining Akcea Therapeutics Inc position as of Q4 2020 after selling out during the quarter.
  • RhumbLine Advisers sold 22,512 Akcea Therapeutics Inc shares in Q4 2020, an estimated $408K.
  • RhumbLine Advisers first reported a position in Akcea Therapeutics Inc in Q3 2017 and held it in 13 quarters.
  • RhumbLine Advisers's Akcea Therapeutics Inc position peaked at $505K in Q4 2018.
  • 0 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q4 2020.

Based on RhumbLine Advisers's 13F filing for Q4 2020, filed 10 Feb 2021.